Cabozantinib (Cometriq®)

Assessment Status Rapid Review complete
Drug Cabozantinib
Brand Cometriq®
Indication Treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma. For patients in whom Rearranged during Transfection (RET) mutation status is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision.
Assessment Process
Rapid review commissioned 10/07/2014
Rapid review completed 12/08/2014
Rapid review outcome Full pharmacoeconomic evaluation recommended at the submitted price.

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.